Moderna Inc.
(MrNa.O) said on Wednesday expected to report data from the Covid-19 vaccine trial in children aged between 2 and 5 years in March.
“If data supports and subject to regulatory consultations, Moderna can continue with the submission of regulations for children aged 2-5 years after,” said the company.
Modern vaccines, based on the RNA Messenger platform, already have authorization in Europe, Britain, Australia and Canada for teenagers aged 12-17 years, and have sent applications for children in 6 to 11 years.
In the United States, this vaccine was authorized by feeding food and drugs as a two-dose primary regimen and a dose of booster for adults aged 18 years and over.
The company, however, has not received authorization from the regulator for the use of its vaccines in children.